by Cathy Kelly, April 15, 2025 The agency’s projection that Medicare will spend $3.5bn on Leqembi in 2025 is nearly three times the level of sales that marketer Eisai is expecting for the drug in North and South America combined in its fiscal year 2026. The Centers for Medicare and Medicaid Services appear to be […]
trialsitenews Staff at TrialSite | Quality Journalism Apr. 12, 2024, 1:00 p.m. Expensive and not always covered by insurance, the standard most reliable method of diagnosing Alzheimer’s disease is via positron emission tomography or PET scan of the brain. Another more cumbersome, invasive and painful approach is the spinal tap. What if there was an […]
Costa Mesa resident Jeannie Weiss is driving Alzheimer’s research forward and is receiving a national award for her exemplary volunteerism to help advance science. The Global Alzheimer’s Platform Foundation (GAP) recognized Weiss for her exceptional role in Alzheimer’s research. Weiss received GAP’s 2023 National Citizen Scientist Champion Award, which is given to individuals who act […]
Purchase of Axiom Brain Health puts Tampa clinical trial site at center of research to find easier way to detect disease in patients. TAMPA — The most reliable way to to diagnose Alzheimer’s disease is through a positron emission tomography or PET scan of the brain, an expensive test not always covered by insurance. Another […]
28th March 2024 Scotland has been selected to host a first-of-its-kind Alzheimer’s research competition, representing ‘significant recognition of the country’s wealth of world-leading expertise,’ says the Chief Scientist for Health Professor Anna Dominiczak welcomed the news that Scotland has already launched the Bio-Hermes Biomarker Data Challenge, granting access to what has been called “the most comprehensive […]
The Global Alzheimer’s Platform Foundation® (GAP) has announced that Scotland will host the Bio-Hermes Biomarker Data Challenge 2024, a groundbreaking research competition utilizing the most extensive collection of dementia biomarker data from innovative early blood testing studies for Alzheimer’s disease. Researchers at the Universities of Glasgow and St. Andrews, under the auspices of the Scottish […]
Washington D.C., Mar. 25, 2024- The Global Alzheimer’s Platform Foundation® (GAP) – which is focused on global game-changing dementia research – has chosen Scotland to host the Bio-Hermes Biomarker Data Challenge 2024, a research competition using the most comprehensive set of dementia biomarker data from ground-breaking early blood testing studies for Alzheimer’s disease. Researchers at […]
Washington D.C., Mar. 20, 2024- Labcorp announced its launch of new blood tests to detect the brain protein called tau. This announcement comes on the heels of the published results of the Bio-Hermes-001 study which reveals a strong correlation between p-tau 217 with the presence of amyloid plaques in the brain, a diagnostic hallmark of […]
POSTED ON MARCH 19, 2024BY CHRIS YOUNG It’s estimated over 580 thousand Floridians are living with Alzheimer’s disease. A study could lead to a simpler way to detect the disease. The study, called Bio-Hermes, showed how new Alzheimer’s detecting blood tests perform across a broad range of races and ethnicities for the first time. Currently, scans or spinal taps […]
By Editor, MAR 16, 2024 WASHINGTON, DC (Feb. 19, 2024) — Today, the Global Alzheimer’s Platform Foundation (GAP) recognized Orange County resident Jeannie Weiss for her exceptional role in Alzheimer’s research. Jeannie Weiss received GAP’s 2023 National Citizen Scientist Champion Award®, which is given to individuals who act as a stimulus in bringing new, novel approaches to Alzheimer’s research […]
08 Mar 2024 ANALYSIS by Cathy Kelly; [email protected] Summary Donanemab’s review delay will create more distance from Lilly’s direct-to-consumer advertising spotlighting its commitment to Alzheimer’s research. The company has also been supporting development of blood-based tools for early diagnoses, though they would not eliminate PET scans. Eli Lilly and Company launched unbranded direct-to-consumer TV advertising […]
Washington D.C., Mar. 08, 2024- The U.S. Food and Drug Administration (FDA) announced today that it expects to convene a meeting of the Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) to discuss the Phase 3 TRAILBLAZER-ALZ 2 trial, which evaluated the efficacy and safety of Donanemab in early symptomatic Alzheimer’s disease. As the […]
By Katharine Lang on March 4, 2024 — Fact checked by Amanda WardA simple blood test, may in the future, help diagnose Alzheimer’s early. Image credit: Oleksii Syrotkin/Stocksy. Dementia currently affects around 60 millionTrusted Source people worldwide, and the number is projected to rise to more than 150 million by 2050. Alzheimer’s disease, the most common form of dementia, causes 60-80% of cases. Available treatments […]
Oral Presentation on Bio-Hermes to Take Place at Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (ADPD) Washington D.C., Mar 04, 2024- Global Alzheimer’s Platform Foundation®, (GAP) is pleased to share that new data from the ground-breaking blood-based and digital biomarker platform study, Bio-Hermes, will be shared by Douglas Beauregard, Project Director of Clinical Operations […]
By Community News Releases -March 2, 2024 The Global Alzheimer’s Platform Foundation (GAP) recently recognized Miami resident Joanne Bridges with the 2023 National Citizen Scientist Collaborator Award. Bridges was selected from a pool of nominees from across North America to receive elevated recognition and be honored for supporting a clinical trial volunteer by serving as […]
LabPulse.com staff writers Mar 1, 2024The first results from the Bio-Hermes study have been released, showing a strong correlation between several blood-based and digital biomarkers with the presence of amyloid plaques in the brain, a diagnostic hallmark of Alzheimer’s disease (AD). The findings from the study, published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, show […]
By LabMedica International staff writersPosted on 29 Feb 2024 Alzheimer’s disease, which traditionally requires costly scans or invasive spinal taps for diagnosis, is now closer to being more easily identified through innovative blood tests. This advancement is particularly crucial with the recent approval of disease-modifying treatments for Alzheimer’s. Now, the results of a study […]
Feb 28, 2024 | Jessica Kim Cohen NEW YORK – Results from blood-based biomarker tests correlated with the presence of beta-amyloid detected using established Alzheimer’s disease diagnostics, according to a study published Wednesday. PET scans and cerebrospinal fluid (CSF) analyses are highly accurate and established methods of identifying elevated levels of beta-amyloid, a hallmark of Alzheimer’s. However, these […]
The results of the Bio-Hermes study appear in Alzheimer’s & Dementia showing how new Alzheimer’s detecting blood tests perform across a broad range of races and ethnicities for the first time. Washington D.C., Feb. 28, 2024- The Global Alzheimer’s Platform Foundation®, (GAP) is releasing the first results from the Bio-Hermes-001 Study. This study in over […]
Researchers and Executives from more than 100+ Alzheimer’s and Parkinson’s clinical trial sites to collaborate on finding a cure for the devastating diseases NEW ORLEANS, La. (Feb. 26, 2024) — From February 28, 2024 through March 1, 2024, the Global Alzheimer’s Platform Foundation (GAP), an organization dedicated to speeding and improving the delivery of Alzheimer’s […]
By Hope Dean, Published: Feb. 21, 2024 at 3:31 PM EST ATLANTA, Ga. (Atlanta News First) – A veteran from Ellenwood is being recognized by a nonprofit foundation for helping advance research on Alzheimer’s disease. Rod Barber won the National Citizen Scientist Catalyst Award, the Global Alzheimer’s Platform Foundation announced on Monday. He has volunteered at CenExel iResearch in […]
Feb. 5 On Thursday, February 1, El Faro Health and Therapeutics played host to a heartfelt Citizen Scientist Award ceremony, honoring Mr. Martin Carrion for his exemplary dedication and advocacy in the realm of Alzheimer’s research. Mr. Carrion’s contributions have not only been commendable but have also left an indelible impact. The ceremony served as […]
The Global Alzheimer’s Platform Foundation’s® (GAP) 2023 Citizen Scientist Award© recipients include a philanthropic Mustang enthusiast, an “old-school” Veteran, an innovative volunteer with Parkinson’s disease and an Alzheimer’s advocate/ inspirational study partner. WASHINGTON, DC (Feb. 19, 2024) — Today, the Global Alzheimer’s Platform Foundation (GAP) proudly announced the 2023 National Citizen Scientist Awards® elevated honorees. […]
Sarasota Researchers Hold FREE Bilingual Memory Screening for Community on Saturday, February 3 Intercoastal Medical Group Neurology & Research Clinic of Sarasota is hosting a FREE memory screening for individuals 50+ to raise awareness for Alzheimer’s Disease Intercoastal Medical Group Neurology and Research Clinic will hold a free memory screening event on Saturday, February 3, […]